Despite the promising benefits, there are several challenges associated with the use of antibiotic loaded nanoparticles in cancer treatment:
1. Toxicity: While nanoparticles can reduce systemic toxicity, the particles themselves can sometimes be toxic. Careful design and testing are required to ensure biocompatibility. 2. Delivery Efficiency: Ensuring that nanoparticles reach the tumor site in sufficient quantities remains a challenge. Factors like blood vessel permeability and the tumor microenvironment can affect delivery efficiency. 3. Regulatory Hurdles: The approval process for new nanoparticle-based therapies can be lengthy and complex, requiring extensive clinical trials to demonstrate safety and efficacy.
